UCB SA (UCB-BT)

QUOTE AND NEWS
FiercePharma  Aug 8  Comment 
MyHealthTeams specialized social networks built around conditions from MS to Spondylitis are adding pharma-sponsored resource centers. Wednesday, it launches its latest with partner UCB to target spondyloarthritis, to offer education and tips to...
FierceBiotech  Jul 13  Comment 
Amgen and UCB have refiled for FDA approval of osteoporosis drug romosozumab one year after the agency rejected a submission on safety grounds. The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a...
The Hindu Business Line  Jul 9  Comment 
Dr Reddy’s Laboratories Ltd and UCB, a biopharmaceutical company, have entered into a distribution and co-promotion agreement for Briviact, a brand o
The Hindu Business Line  Jul 9  Comment 
Dr Reddy’s Laboratories Ltd and UCB, a biopharmaceutical company, today announced they have entered into a distribution and co-promotion agreement fo
The Economic Times  Jun 25  Comment 
​Currently, the Board of Directors of a UCB perform both the executive and supervisory roles and has the responsibility to oversee the overall functioning of the bank.
FiercePharma  May 20  Comment 
Women with inflammatory bowel disease can experience difficulties around pregnancy specific to their condition. However, there is no standard treatment plan shared by the multiple care teams typically involved. To help change that, UCB is...
GenEng News  Apr 20  Comment 
UCB said today it has acquired rights to Proximagen’s NDA-bound anti-epilepsy candidate Midazolam Nasal Spray (USL261)1 for up to $370 million. Midazolam is being developed as a rescue treatment for acute repetitive seizures (ARS, also known...
GenEng News  Apr 5  Comment 
Reflecting growing interest in developing targeted therapies using genomic insights, UCB said today it has acquired Duke University spinout Element Genomics for up to $30 million. UCB said the deal was designed to strengthen its genomics and...





You may also be interested in articles related to Ucb sa (ucb-bt):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki